苏黄止咳胶囊联合噻托溴铵治疗慢性阻塞性肺疾病稳定期临床研究
CSTR:
作者:
中图分类号:

R563


Clinical Study on Suhuang Zhike Capsules Combined with Tiotropium Bromide for Chronic Obstructive Pulmonary Disease at Stable Stage
  • 摘要
  • | |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • |
  • 引证文献
  • | |
  • 文章评论
    摘要:

    目的:观察苏黄止咳胶囊联合噻托溴铵治疗慢性阻塞性肺疾病(COPD) 稳定期的临床疗效。方法:选取120 例COPD 稳定期患者,根据治疗方法不同分为对照组和观察组各60 例。对照组给予噻托溴铵治疗,观察组在对照组基础上加用苏黄止咳胶囊治疗,2 组均治疗3 个月。比较2 组治疗前后肺功能指标、血清炎症因子水平、6 min 步行距离、圣乔治呼吸疾病问卷(SGRQ) 评分;比较2 组临床疗效。结果:治疗后,2 组第1 秒用力呼气容积(FEV1)、用力肺活量(FVC) 水平及FEV1/FVC 均较治疗前升高(P<0.05),观察组FEV1、FVC 水平及FEV1/FVC 均高于对照组(P<0.05)。观察组总有效率为91.67%,高于对照组的78.33% (P<0.05)。治疗后,2 组血清超敏C-反应蛋白(hs-CRP)、白细胞介素-17 (IL-17)、白细胞介素-8(IL-8) 水平均较治疗前降低(P<0.05),观察组上述血清炎症因子水平均低于对照组(P<0.05)。治疗后,2 组6 min 步行距离均较治疗前增加(P<0.05),SGRQ 评分均较治疗前降低(P<0.05);观察组6 min 步行距离大于对照组(P<0.05),SGRQ 评分低于对照组(P<0.05)。结论:苏黄止咳胶囊联合噻托溴铵治疗COPD 稳定期可提高临床疗效,改善患者的肺功能和生活质量,降低血清炎症因子水平。

    Abstract:

    Abstract: Objective: To observe the clinical effect of Suhuang Zhike capsules combined with tiotropium bromide for Chronic obstructive pulmonary disease(COPD) at stable stage. Methods: A total of 120 cases of COPD patients at stable stage were selected and divided into the control group and the observation group according to different treatment methods, 60 cases in each group. The control group was treated with tiotropium bromide,and the observation group was additionally treated with Suhuang Zhike capsules based on the treatment of the control group. Both groups were treated for three months. The lung function indexes,levels of inflammatory factors in serum,6-minute walking distance,and scores of St. George's Respiratory Questionnaire(SGRQ) were compared between the two groups. The clinical effect was compared between the two groups. Results:After treatment,forced expiratory volume in one second(FEV1),forced vital capacity(FVC),and FEV1/ FVC in the two groups were increased when compared with those before treatment(P<0.05),and the three indexes in the observation group were higher than those in the control group(P<0.05). The total effective rate was 91.67% in the observation group,higher than that of 78.33% in the control group,the difference being significant(P<0.05). After treatment,levels of high- sensitivity C- reactive protein(hs- CRP), interleukin- 17(IL- 17), and interleukin- 8(IL- 8) in the two groups were decreased when compared with those before treatment(P<0.05),and the levels of the three inflammatory factors above in the observation group were lower than those in the control group(P<0.05). After treatment,6-minute walking distance in the two groups was increased when compared with that before treatment(P<0.05),and the SGRQ scores were decreased(P< 0.05); 6- minute walking distance in the observation group was larger than that in the control group(P<0.05), and SGRQ score was lower(P<0.05). Conclusion: In the treatment of COPD at stable stage, the therapy of Suhuang Zhike capsules combined with tiotropium bromide can enhance clinical effect,improve the lung function and quality of life,and reduce levels of inflammatory factors in serum.

    参考文献
    相似文献
    引证文献
引用本文

谢维艳,谢颖,姜建平.苏黄止咳胶囊联合噻托溴铵治疗慢性阻塞性肺疾病稳定期临床研究[J].新中医,2021,53(18):52-55

复制
分享
文章指标
  • 点击次数:
  • 下载次数:
  • HTML阅读次数:
  • 引用次数:
历史
  • 在线发布日期: 2021-09-24
文章二维码